Addressing the bottlenecks associated with next generation sequencing in translational research by offering a robust platform for targeted sequencing applications

ArcherDX is a commercial stage company utilizing novel chemistry for next generation sequencing to provide research tools to leading universities and pharmaceutical companies. By combining proprietary Anchored Multiplexed PCR chemistry in an easy-to-use, lyophilized format with a powerful bioinformatics platform, ArcherDX technology dramatically enhances genetic mutation identification and discovery. ArcherDX is developing a suite of companion diagnostics based on this technology, initially targeting mutations across numerous cancer types to enable wider adoption of precision medicine.

Visit Site

Related Press